NEJM:早期宫颈癌根治术对患者全因死亡率的影响

2018-11-15 zhangfan MedSci原创

研究认为,早期宫颈癌患者采用微创根治性子宫切除术的总生存率比开放手术要短

近日研究人员就早期宫颈癌根治性子宫切除术对患者全因死亡率的影响进行了考察。

2010-13年间,接受根治性子宫切除术的IA2或IB1期宫颈癌患者参与研究,随机接受微创手术或开腹手术,研究的主要终点为全因死亡率。

2461名患者参与研究,其中49.8%接受微创手术,微创手术人群白人、拥有私人保险和较高社会经济地位的人居多,其肿瘤较小,级别较低。平均随访45个月,微创组患者4年死亡率为9.1%,而开腹手术组为5.3%(HR=1.65)。流行病学发现接受微创手术的患者头4年的生存率保持基本稳定,年度差异不超过0.3%,但4年后生存率则每年下降约0.8%。

研究认为,早期宫颈癌患者采用微创根治性子宫切除术的总生存率比开放手术要短。

原始出处:

Alexander Melamed et al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.N Engl J Med, November 15, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1251505, encodeId=eda712515052b, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399724, encodeId=90941399e241d, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408154, encodeId=a1091408154a8, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586122, encodeId=9d5415861226c, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1251505, encodeId=eda712515052b, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399724, encodeId=90941399e241d, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408154, encodeId=a1091408154a8, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586122, encodeId=9d5415861226c, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1251505, encodeId=eda712515052b, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399724, encodeId=90941399e241d, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408154, encodeId=a1091408154a8, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586122, encodeId=9d5415861226c, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2018-11-17 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1251505, encodeId=eda712515052b, content=<a href='/topic/show?id=874529332ba' target=_blank style='color:#2F92EE;'>#全因死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29332, encryptionId=874529332ba, topicName=全因死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399724, encodeId=90941399e241d, content=<a href='/topic/show?id=72406223398' target=_blank style='color:#2F92EE;'>#根治术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62233, encryptionId=72406223398, topicName=根治术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=03a52234941, createdName=bluefate122, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408154, encodeId=a1091408154a8, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586122, encodeId=9d5415861226c, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sat Nov 17 00:15:00 CST 2018, time=2018-11-17, status=1, ipAttribution=)]
    2018-11-17 jeanqiuqiu

相关资讯

NCCN临床实践指南:宫颈癌(2019.V2)

2018年10月,美国国家综合癌症网络(NCCN)发布了宫颈癌指南2019年第2版,指南主要内容包括: 指南更新摘要: 宫颈癌临床分期 子宫切除术后偶发侵袭性肿瘤 监测 局部/区域性复发 远处转移 影像学检查原则 评估和手术分期原则 宫颈癌放疗原则 淋巴结阴性,边缘阴性患者根治性子宫切除术后外部盆腔放疗标准 复发或转移性宫颈癌的化疗方案 分期

Nat Commun:我国科学家发现人乳头瘤病毒促进宫颈癌的机制!

最近研究报道HPV16的E7是更有说服力的致癌启动子。但E7蛋白造成宫颈癌的新机制和人乳头瘤病毒怎样控制细胞内活性氧水平仍有待发现。

NEJM:早期宫颈癌患者接受开腹根治术的预后效果优于微创手术

研究认为对于早期宫颈癌患者接受传统的开腹根治性子宫切除术可提高预后

2017 JSGO指南:宫颈癌的治疗

2017年修订版JSGO宫颈癌的治疗指南主要提出了宫颈癌的标准治疗策略,全文共包括8章内容,涉及不同分期的宫颈癌的初始治疗,复发性宫颈癌的治疗,妊娠期宫颈癌的治疗以及治疗后监测等。

Lancet oncol:多少岁可停止进行宫颈癌筛查?

目前,该在多少岁时停止宫颈癌筛查的实验性证据不足。一般全球推荐的停止筛查的年龄在50-70岁之间。但是,宫颈癌在老年女性中的发病率和死亡率仍然很高。Talia Malagon等人采用宫颈癌筛查的Markov模型来评估不同年龄停止宫颈癌筛查后的宫颈癌风险,以此确定适合停止宫颈癌筛查的年龄。研究人员建立了宫颈癌病史和筛查的状态转换(Markov)模型,并采用官方数据进行校准和验证。为模拟该模型的年龄结

CLIN CANCER RES:骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志

CLIN CANCER RES近期发表了一篇文章,研究同步放化疗(CCRT)期间身体成分变化与局部晚期宫颈癌(LACC)患者预后之间的关系。